Myelodysplastic Syndromes Treatment (PDQ®): Treatment - Health Professional Information [NCI]-Genera
Myelodysplastic Syndromes Treatment (PDQ®): Treatment - Health Professional Information [NCI]-General Information About Myelodysplastic Syndromes
Myelodysplastic Syndromes Treatment (PDQ®): Treatment - Health Professional Information [NCI] Guide
Risk Factors
Approximately 90% of MDS cases occur de novo with no identifiable cause. Potential environmental risk factors for developing MDS include exposure to the following:[7,8]
Related Summary
A PDQ summary containing information about myelodysplastic syndromes in children is:
References:
Myelodysplastic Syndromes Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information About Myelodysplastic Syndromes
Myelodysplastic Syndromes Treatment (PDQ®): Treatment - Health Professional Information [NCI] Guide
- General Information About Myelodysplastic Syndromes
- Pathologic and Prognostic Systems for Myelodysplastic Syndromes
- Treatment for Myelodysplastic Syndromes
- Relapsed or Refractory Myelodysplastic Syndromes
- Current Clinical Trials
- Changes to This Summary (12 / 03 / 2012)
- About This PDQ Summary
- Get More Information From NCI
Risk Factors
Approximately 90% of MDS cases occur de novo with no identifiable cause. Potential environmental risk factors for developing MDS include exposure to the following:[7,8]
- Tobacco smoke.
- Ionizing radiation.
- Organic chemicals (e.g., benzene, toluene, xylene, and chloramphenicol).
- Heavy metals.
- Herbicides.
- Pesticides.
- Fertilizers.
- Stone and cereal dusts.
- Exhaust gases.
- Nitro-organic explosives.
- Petroleum and diesel derivatives.
Related Summary
A PDQ summary containing information about myelodysplastic syndromes in children is:
- Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies.
References:
- Ma X, Does M, Raza A, et al.: Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109 (8): 1536-42, 2007.
- Sekeres MA, Schoonen WM, Kantarjian H, et al.: Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 100 (21): 1542-51, 2008.
- Tuncer MA, Pagliuca A, Hicsonmez G, et al.: Primary myelodysplastic syndrome in children: the clinical experience in 33 cases. Br J Haematol 82 (2): 347-53, 1992.
- Gyger M, Infante-Rivard C, D'Angelo G, et al.: Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes. Am J Hematol 28 (1): 13-20, 1988.
- Tiu RV, Gondek LP, O'Keefe CL, et al.: Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 117 (17): 4552-60, 2011.
- Nand S, Godwin JE: Hypoplastic myelodysplastic syndrome. Cancer 62 (5): 958-64, 1988.
- Du Y, Fryzek J, Sekeres MA, et al.: Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS). Leuk Res 34 (1): 1-5, 2010.
- Strom SS, Gu Y, Gruschkus SK, et al.: Risk factors of myelodysplastic syndromes: a case-control study. Leukemia 19 (11): 1912-8, 2005.
Source...